| Dietary phospholipids, hepatic lipid metabolism and cardiovascular disease |  |
|
| LDL Lowering in Type 2 Diabetes | |
|
| ‘Real-life’ reduction in cholesterol with statins, 1993 to 2002 | |
|
| Risk Factor Associations With the Presence of a Lipid Core in Carotid Plaque of Asymptomatic Individuals Using High-Resolution MRI |
|
|
| Clinical Outcomes by Race in Hypertensive Patients With and Without the Metabolic Syndrome |
|
|
| Diagnosing familial hypercholesterolaemia: the relevance of genetic testing |
|
|
| Apo B versus cholesterol in estimating cardiovascular riskand in guiding therapy: report of the thirty-person/tencountry panel |
|
|
| Performance of trans-free vegetable oils in shortenings and deep-fat frying | |
|
| New targets and emerging therapies for reducing LDL cholesterol | |
|
| Atherosclerosis and lipoproteins: vascular cell senescence and atherosclerosis | |
|
| Apheresis Technologies and Clinical Applications: The 2005 International Apheresis Registry |
|
|
| Adiponectina e IMT | |
|
| COL - Phytosterols | |
|
| Dieta e HTA | |
|
| LDL Oxidadas | |
|
| Medicion IMT | |
|
| Omega3 | |
|
| Risk Scoring | |
|
| Biomarkets | |
|
| Mas sobre Field | |
|
| ATP III | |
|
(Volver)
